US20170319105A1 - Systems and methods for quantification of, and prediction of smoking behavior - Google Patents
Systems and methods for quantification of, and prediction of smoking behavior Download PDFInfo
- Publication number
- US20170319105A1 US20170319105A1 US15/619,109 US201715619109A US2017319105A1 US 20170319105 A1 US20170319105 A1 US 20170319105A1 US 201715619109 A US201715619109 A US 201715619109A US 2017319105 A1 US2017319105 A1 US 2017319105A1
- Authority
- US
- United States
- Prior art keywords
- patient
- carbon monoxide
- samples
- individual
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006399 behavior Effects 0.000 title claims abstract description 77
- 230000000391 smoking effect Effects 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000011002 quantification Methods 0.000 title 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 21
- 230000003542 behavioural effect Effects 0.000 claims abstract description 7
- 235000019504 cigarettes Nutrition 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 abstract description 91
- 238000004458 analytical method Methods 0.000 abstract description 12
- 230000005586 smoking cessation Effects 0.000 abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000004048 modification Effects 0.000 abstract description 6
- 238000012986 modification Methods 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000036765 blood level Effects 0.000 abstract description 2
- 238000011277 treatment modality Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 43
- 230000011664 signaling Effects 0.000 description 22
- 210000003296 saliva Anatomy 0.000 description 13
- 238000004891 communication Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000009223 counseling Methods 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002670 nicotine replacement therapy Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/082—Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4845—Toxicology, e.g. by detection of alcohol, drug or toxic products
Definitions
- the present invention generally relates to the field of behavioral modification.
- exemplary embodiments of the present invention are directed to extracorporeal devices, systems and methods for facilitating cessation of undesired behaviors.
- Certain persons may engage in certain undesirable activities that have significant negative acute and/or long-term health, social, and safety implications for the person and for other associated persons.
- the person may wish to quit this behavior.
- the person's family, friends, and/or healthcare providers are also engaging with the person in an attempt to have them quit the behavior.
- Associated persons may also be negatively impacted by the behavior, socially, financially, and from a health perspective.
- Such behavioral modification or cessation attempts to terminate the undesirable behavior may be formal and administered by healthcare professionals, or the person may take their own personalized approach to cessation.
- An example of such a behavioral modification program is a formal multi-modality smoking cessation program that utilizes counseling and drug therapy to achieve the end goal of abstinence from smoking.
- Drug therapy typically includes one or more of: nicotine replacement therapy, welbutryn, varenicline, and other drugs.
- Alcohol cessation programs by comparison, may include similar approaches with counseling and drug interventions targeted specifically to achieve abstinence from alcohol use and abuse.
- a typical multi-modality smoking cessation program participants are asked to voluntarily and honestly report on their smoking behavior before and during therapy.
- the patient's baseline smoking behavior is measured according to the patient's own voluntary report and is based solely on their recall (i.e., patient states that they average forty cigarettes per day prior to entering program).
- the patient may also be asked to provide a blood sample at the clinic or hospital location to test for substances associated with smoking behavior, such as hemoglobin bound to carbon monoxide.
- the patient may be asked to exhale into a device at the clinic or hospital location to detect carbon monoxide levels in the exhaled gas from the lungs.
- Such tests would be performed on location and observed by the health care provider, and such tests may require processing by a professional laboratory.
- a gross estimate of smoking behavior may be made by the health care professional. Limitations of such testing are that it is made at a single point in time and likely does not fully and accurately reflect the true behavior of the patient at multiple time points before entering the program. The patient may alter their behavior, for example, for days prior to testing thus making the test result less relevant and accurate.
- the patient's interval smoking behavior since the previous visit is quantified by patient voluntary reporting (recollection, diary, etc.). For example, if the patient is seen weekly, they will report on their smoking behavior for the prior seven days. Typically, the patient keeps a diary or smoking log during each interval in which daily entries are made regarding the number of cigarettes smoked and certain lifestyle events that occur in conjunction with smoking behavior. This methodology relies on compliance and full disclosure by the smoker, as well as a commitment to record the data every day.
- a method for facilitating cessation of undesired behavior in a patient includes steps such as configuring a patient device with a predetermined test protocol including patient test prompts, prompting the patient in accordance with the predetermined test protocol to provide at least one biological input to the patient device, the biological input being correlated to the undesired behavior, analyzing the patient biological input to the patient device, generating a machine readable data set representative of the patient input based on the analyzing, associating the data set with a specific patient biological input, evaluating the predetermined test protocol based on the data set, and altering or maintaining the predetermined test protocol based on the evaluation.
- such a method may also include steps of determining whether the patient properly provided a biological input in response to the prompting, and re-prompting the patient to provide the at least one biological input when the determining result is negative.
- Other aspects of exemplary embodiments may include remotely reconfiguring the test protocol in the patient device through a communications network, prompting the patient to input requested information to the patient device through a user interface, and associating the requested information with the data set associated with a specific patient's biological input. Additionally, the evaluating may be based on the requested information associated with the data set.
- methods according to the present invention may include transmitting the data set and associated requested information to a health care provider device.
- Other optional steps may include communicating with the patient device through a network, and prompting the patient to provide at least one biological input outside of the predetermined test protocol.
- exemplary embodiments may also include collecting data related to the patient undesired behavior, and analyzing the patient behavior data to determine the predetermined test protocol.
- system for facilitating cessation of undesired behavior in a patient includes a patient device or PD and a health care provider device or HCPD that are configured to communicate with one another through a network or other known means of data transfer.
- the PD may be configured and dimensioned to be carried by the patient, may include a PD user interface, a test element configured to receive a biological input from the patient and output information representative of the content of the biological input, a PD storage module containing instructions for various functions including for a predetermined test protocol, and a PD execution module communicating with the user interface, the test element and the storage module, the PD execution module configured to execute instructions contained in said PD storage module.
- the predetermined test protocol instructions may, for example, include prompting the patient through the user interface to provide a biological input to the test element at selected intervals, determining the completeness of a biological input, and providing additional patient prompts based on the completeness determination.
- an HCPD may be configured to be accessed by a health care provider, and include an HCPD user interface, an HCPD storage module containing certain instructions and an HCPD execution module communicating with the user interface and storage module, the execution module configured to execute instructions contained in the HCPD storage module.
- Instructions stored in the HCPD storage module may include instructions for displaying and manipulating information representative of the content of the biological input, and revising the predetermined test protocol based on at least one of user input and the information representative of the content of the biological input.
- instructions for executing some functions may be stored in either the PD or HCPD storage modules and executed by the associated execution modules as appropriate. Examples of such instructions may include instructions for generating a machine readable data set based on the test element output information, and for associating the data set with a specific patient biological input, or instructions for causing the patient device to prompt the patient to input requested information to the patient device through the PD user input and for associating the requested information with a data set associated with a specific patient biological input.
- the patient device may further include an identification device for acquiring patient identifying information correlated to a biological input.
- an identification device may communicate with the storage module and execution module for associating the acquired identifying information with the correlated biological input and storing the associated identifying information.
- the system may also permit receiving unprompted patient input through the PD user input and then associating the unprompted input with a biological input based on a predetermined algorithm.
- an apparatus for use in connection with facilitating cessation of undesired behavior in a patient may include at least one housing configured and dimensioned to be carried by the patient, a user interface disposed in the at least one housing, a test element disposed in the at least one housing, the test element being configured to receive a biological input from the patient and output information representative of the content of the biological input, a storage module containing instructions related to the operation of the apparatus, and an execution module communicating with the user interface, the test element and the storage module.
- Exemplary instructions contained in the storage model may include instructions for executing a predetermined test protocol, b) generating user readable indicator based on the test element output and displaying the output on the user interface, associating the user readable indicator with a specific biological input, associating the requested information with a specific user readable indicator associated with a specific patient biological input, and storing test result information including the user readable indicator and associated requested information in the storage module.
- the predetermined test protocol instructions may include steps of prompting the patient through the user interface to provide a biological input to the test element at selected intervals, determining the completeness of a biological input, providing additional patient biological input prompts based on the completeness determination, and prompting the patient to input requested information through the user interface.
- the apparatus may be configured to communicate through a network for transfer of the test result information.
- a method for collecting and confirming patient participation in select behaviors may include steps such as configuring a patient device with a predetermined test protocol including patient test prompts, prompting the patient in accordance with the predetermined test protocol to provide at least one biological input to the patient device, the biological input being correlated to the select behavior, determining whether the patient properly provided a biological input in response to the prompting, re-prompting the patient to provide the at least one biological input when the determining result is negative, analyzing the patient biological input to the patient device, generating a machine readable data set representative of the patient input based on the analyzing, associating the data set with a specific patient biological input, prompting the patient to input requested information to the patient device through a user interface, associating the requested information with the data set associated with a specific patient biological input, evaluating the predetermined test protocol based on the data set and the requested information associated with the data set.
- FIG. 1 is a block diagram illustrating a patient monitoring device according to an exemplary embodiment of the present invention.
- FIG. 2 is a diagram illustrating a system according to an exemplary embodiment of the present invention.
- FIG. 3 is a flow chart illustrating a method according to an exemplary embodiment of the present invention.
- Embodiments of the present invention provide devices, methods and systems capable of prompting a patient to perform self-testing for undesired behaviors, objectively analyzing the test results, logging the data to a local or central storage unit, and providing a comprehensive interface for the patient and healthcare professional to analyze and observe results and correlate these results with progress within a cessation program.
- Such self-testing may be according to a protocol that is monitored and altered in real time to adapt to specific circumstances of the patient's needs.
- a number of undesirable behaviors that involve smoking of one or more substances, oral ingestion of one or more substances, oral placement of one or more substances, transdermal absorption of one or more substances, nasal sniffing of one or more substances, and other methods of absorbing one or more substances result in the subsequent presence of one or more of the substances in the exhaled breath.
- the presence of a unique substance or substances in the exhaled breath can be used as a marker for the specific undesirable behavior and intermittent testing of the exhaled breath for this substance(s) can quantify the occurrence of the undesirable behavior.
- Such substances may be detected in the exhaled breath due to one or more of the following mechanisms: 1) the substance was previously absorbed into the body and bloodstream and is then released from the bloodstream into the pulmonary airspace for exhalation, 2) the substance was very recently inhaled into the pulmonary dead space (non-absorbing portion of inhaled air) and is being exhaled acutely therefore not requiring a blood level of the substance to be present, 3) the substance is present in the oral cavity mucous and epithelial surface layers and certain portions volatilized into the exhaled breath, 4) the substance was previously absorbed into the body and bloodstream and is then released from salivary glands into the oral cavity in the saliva and then volatilized into the exhaled breath, and/or 5) the substance was exhaled previously and a portion of the substance was retained within the oral cavity mucous and epithelial surface layers and certain portions subsequently volatilized into the exhaled breath.
- One alternative to intermittently testing the exhaled breath to detect one or more substances associated with an undesirable behavior is to intermittently test saliva for one or more substances associated with an undesirable behavior, as these substances as disclosed above often reside in the oral cavity via secretion within the saliva from the bloodstream or accumulation within the oral cavity mucous, saliva, and epithelial lining due to ingestion or exhalation residues.
- high quality objective data collected in an improved manner could be used by the healthcare professional to adjust therapy (i.e., nicotine replacement therapy, other drug therapy, counseling, etc.) to achieve a better outcome, to provide real-time or delayed positive and negative feedback to the patient, to determine success or failure of the cessation program, and to provide long-term maintenance of cessation after successfully quitting the behavior (avoidance of recidivism).
- therapy i.e., nicotine replacement therapy, other drug therapy, counseling, etc.
- the dose of the NRT could be immediately increased and/or other therapies could be added with this approach.
- the various therapies could be titrated downward and ultimately discontinued.
- patient device 10 includes two main components: extra-corporeal detector unit 12 containing at least one test element and signaling unit 16 .
- extra-corporeal detector unit 12 containing at least one test element
- signaling unit 16 The components may be combined into a single unit or may be separated physically. Other embodiments may include additional components and these components may be combined or separate as well.
- Extra-corporeal detector unit 12 includes at least one test element that is capable of detecting a substance in a biological input from the patient that is indicative of recent targeted behavior.
- the detector analyzes the biological input from the patient, such as expired gas from the lungs or saliva, and in at least one embodiment logs the date and time of day, quantifies the presence of the targeted substance(s), and then stores the data for future analysis and/or sends the data to a remote location for analysis.
- Detector unit 12 thus may include a processor, memory and user interface 14 as appropriate for its specific functions.
- the user interface may include data inputs such as a touch screen, keyboard or pointer.
- Detector units may be specifically configured by person of ordinary skill in the art for detection of specific marker substances related to targeted behaviors as described herein.
- substances detected related to smoking include but are not limited to carbon monoxide, nitrogen oxides, ammonia, arsenic, nicotine, acetone, acetaldehyde, formaldehyde, hydrogen cyanide, isoprene, methyl ethyl ketone, benzene, toluene, phenol, and acrylonitrile.
- Sensor technologies for detecting alcohol in the exhaled breath include infrared spectrophotometer technology, electrochemical fuel cell technology, or a combination of the two. Smaller portable units well suited for use in embodiments of the invention may be based on electrochemical fuel cell analysis or “Taguchi cell” sensors.
- U.S. Pat. No. 7,797,982 entitled “Personal Breathalyzer Having Digital Circuitry.”
- Another example of detector units that may be configured to determine the presence of a variety of substances is disclosed in U.S. Pat. No. 7,421,882, entitled “Breath-based Sensors for Non-invasive Molecular Detection.”
- U.S. Pat. No. 7,525,093, entitled “Liquid or Gas Sensor and Method” discloses another sensor device that may be readily incorporated into embodiments of the present invention by persons of ordinary skill in the art.
- Each of the forgoing U.S. patents are incorporated by reference herein in their entirety.
- Detector unit 12 may also be configured to recognize a unique characteristic of the patient, such as a fingerprint, retinal scan, voice label or other biometric identifier, in order to prevent, at least to a degree, having a surrogate respond to the signaling and test prompts to defeat the system.
- patient identification sub-unit 15 may be included in detector unit 12 .
- Persons of ordinary skill in the art may configure identification sub-unit 15 as needed to include one or more of a fingerprint scanner, retinal scanner, voice analyzer, or face recognition as are known in the art. Examples of suitable identification sub-units are disclosed, for example in U.S. Pat. No. 7,716,383, entitled “Flash-interfaced Fingerprint Sensor,” and U.S. Patent Application Publication No. 2007/0005988, entitled “Multimodal Authentication,” each of which is incorporated by reference herein in their entirety.
- Identification sub-unit 15 may also comprise a built in still or video camera, which would record a picture or video of the patient automatically as the biological input is provided to the test element. Regardless of the type of identification protocol used, the processor and memory in the detector unit will associate the identification with the specific biological input, for example by time reference, and may store that information along with other information regarding that specific biological input for later analysis.
- a patient may also attempt to defeat the detector by blowing into the detector with a pump, bladder, billows, or other device, for example, when testing exhaled breath.
- a patient may attempt to substitute a “clean” liquid such as water. While no means will absolutely prevent an uncooperative and determined patient from these attempts, some means to defeat these attempts can be incorporated in to the system.
- the detector unit may incorporate the capability of discerning between real and simulated breath delivery. In one exemplary embodiment this functionality may be incorporated by configuring detector unit 12 to sense oxygen and carbon dioxide, as well as the maker substance (carbon monoxide, etc.).
- the detector is able to confirm that the gas being analyzed is truly coming from expired breath, as expired breath has lower oxygen and much higher carbon dioxide than ambient air.
- the detector unit may be additionally configured to detect enzymes naturally occurring in saliva so as to distinguish between saliva and other liquids. Basic biochemical tests are well known to persons skilled in the art for identifying such substances.
- Signaling unit 16 may communicate with detector unit 12 through an appropriate communication link 20 (for example, wired, WI-FI, Bluetooth, RF, or other means) as may be devised by a person of ordinary skill in the art based on the particular application.
- Signaling unit 16 may be integrated with detector unit 12 in patient device 10 or may separate from the detector unit, but the units are synchronized and able to communicate real-time or at various intervals in order to correlate signaling and detector results.
- signaling unit 16 may include its own processor, memory and graphical user interface 18 , but when integrated with detector unit 12 both units may share one of more of those subcomponents.
- signaling unit 16 prompts the patient to blow into the detector unit at various times of the day, and/or prompts the patient to test their saliva or other body fluid as appropriate for the specific detector unit input.
- memory for detector unit 12 and signaling unit 16 will contain instructions appropriate for operation of the patient device in accordance with the various method embodiments described herein.
- a prompt to test may have to be ignored for reasons not considered noncompliant due to the patient being engaged in an activity that prevents testing, such as exercise, work, driving, etc.
- a means by which to delay testing in response to a prompt such as “snooze button” 19 may be incorporated. For example, if a patient is driving a vehicle, they may push button 19 to activate a preset interval until the test is again requested. A certain number of delays may be permitted each day, with this number being set by the provider or patient in the program.
- Signaling unit 16 may also include means permitting the patient to input information that the patient believes relevant to his or her condition without prompting.
- information may, for example, include information about the patient's state of mind, that is feeling stressed or anxious.
- unprompted information could then be correlated to a biological input based on a predetermined algorithm, such as being associated with the biological input that is closest in time to the unprompted input, or associated with the first biological input occurring after the unprompted input.
- detector and signaling units 12 , 16 are combined and exist in an entirely portable configuration with battery power. Such embodiments may also be provided with network connection capability (WI-FI, wireless cell, RF, etc.) as described in greater detail below.
- WI-FI wireless cell, RF, etc.
- a PDA-like device that is able to both signal the patient as well as perform the expired gas analysis could be carried in the patient's pocket at all times and improve compliance by the patient by allowing them to respond immediately to notifications.
- the signaling unit may be configured to be worn as a wristwatch or carried like a PDA. Likewise, the detector would be worn or carried, but separately.
- the units are time synchronized or linked via a wireless communication link 20 to allow analysis of the time dependent data (linking of the notification and exhalation events).
- either the detector or the signaling unit could act as the storage entity for the data utilizing its own internal memory.
- either could act as the sending unit to upload the data to a remote source for live tracking of patient data as described in more detail below.
- Data could be uploaded immediately, intermittently or not at all.
- the data could also be downloaded from the storage media either by the patient or health care professional
- system 30 includes mobile patient devices 10 (including integrated detector and signaling units) and/or stand alone detector units 12 that communicate through network 32 with healthcare provider base station 34 .
- Network 32 may comprise the Internet, a land-based or cellular telephone network or any other communications networks or combination of networks as appropriate for the particular patients and cessation program.
- Healthcare provider base station 34 may comprise a specially programmed personal computer in a doctor's office linked to communication network 32 through an appropriate communications buss or a specialized device including its own memory, processor and graphical user interface. Persons of ordinary skill in the art may configure and program base station 34 based on the teachings contained herein.
- System 30 also may include fixed patient devices 36 .
- Fixed patient devices may comprise substantially the same components as mobile patient devices 10 except that they are configured to be fixed at a particular location such as a patient's home, office or automobile.
- system 30 permits remote programming by the healthcare provider as appropriate for the particular patient and/or cessation program. An exemplary method for implantation of a cessation program utilizing system 30 is described in greater detail with reference to the flow chart of FIG. 3 .
- system 30 may be preprogrammed to prompt the patient at specific times (step 40 ) and/or the healthcare provider (HCP) may randomly prompt the patient (step 42 ) when there is a concern that behavior is timed to avoid preprogrammed prompts.
- the programmed prompts 40 may occur at random intervals as described in more detail below.
- patient devices 10 may be programmed to be operational during prescribed hours (typically waking hours, for example from 6 am to 11 pm), although sleep hour function can be activated. The patient is prompted at various times throughout the day to exhale into the detector. The patient is instructed (step 44 ) with each prompt regarding how to properly and consistency perform the requested test.
- the patient will take several full breaths in and out into the detector, followed by a deep test exhalation for the detector to analyze.
- a determination is then made (step 46 ) as to whether the patient has complied. Circumstances of non-compliance may also be determined (step 48 ). For example if device 10 determines that there was simply no attempt at compliance the patient may be re-instructed a set number of times (branch 50 ). However, after a predetermined number of re-instructions without compliance, the device simply may report a non-compliant episode (branch 52 ). Alternatively, if it is determined that the patient attempted to comply but compliance was incomplete (for example, does not exhale fully) then the test may be rejected and the patient instructed to repeat the test (branch 50 ).
- the sample is analyzed (step 56 ) according to the predetermined detector unit protocol. Marker substances, if present, may be quantified at each test interval if such analysis is included in the protocol.
- Each event may be reported (step 58 ), either in real time through network communications or via periodic downloads.
- data regarding the qualitative (yes/no) values as well as the quantitative substance level may be stored within the detector in a memory unit such as a flash drive or disk.
- a storage medium may be used to transfer stored data to a health care provider device, thus providing communication to the patient device and health care provider device.
- the unit may upload the data live via a cell connection or local network.
- Such upload may occur intermittently or immediately. Disk space may be freed up upon confirmation of successful upload, as needed.
- Reported events are analyzed (step 60 ), for example by being categorized as either negative or positive for the substance of interest based on a pre-determined threshold for positivity, and therefore negative or positive for the smoking behavior.
- the threshold for positivity may be set at standard levels derived from the scientific literature or may be adjusted by the healthcare professional to the specific needs of the patient. Such adjustments may occur in real time based on data analysis and may include changes in the testing as well as prompting protocols.
- the event is interpreted as a failure and flagged in the database.
- Data analysis can interpret failed tests as being positive for smoking behavior or may omit the value entirely.
- the analysis tool is capable of variably dealing with such failed signals for testing. If considered positive for a smoking behavior, a positive quantitative value may be assigned to that data point. Such a design prevents the patient from gaining a benefit (logging a negative data point) by ignoring a signal if they were engaging in smoking at the time of the signal to test.
- Programming necessary to implement the exemplary methodology illustrated in FIG. 3 may exist entirely within software or firmware resident in patient device 10 , divided between detector unit 12 and signaling unit 16 as appropriate for the particular configuration of the device. Alternatively, such programming may at least in part reside in a server or other source associated with base station 34 , communicating with patient devices 10 and 36 and/or detector unit 12 through communications network 32 .
- an advantage of the present invention is that it may be specifically configured for individual patients so that the detector and signaling unit can be with the patient at all times. The patient is thus able to respond to a signaling notification within the allotted and permitted time interval (i.e., within about 2-10 minutes) at all times and may not use lack of availability as an excuse for noncompliance.
- the patent prompts are programmed to be intermittent and of varying intervals, so as not to be predictable.
- the frequency of prompting can vary throughout the day, and the pattern can be unpredictable and non-repeating, thus preventing the patient from predicting when they will be notified to blow into the detector or test saliva.
- the healthcare provider may initiate additional prompts through network 32 when in appropriate circumstances. This unpredictability and variability prevents the patient from modifying the timing of their smoking behavior in such a manner so as to avoid detection of the smoking behavior or to minimize the quantitative result of the test.
- the number of signaling events per day can vary, for example on one day twenty signals may be delivered, while on the next day only twelve are delivered.
- Variability can be important, for example, if the signaling unit notified the patient every hour on the hour, the smoker could smoke three cigarettes immediately after the hour then avoid smoking for the remainder of the hour until prompted next. Presumably, during that hour-long interval of no smoking, the substance detected in expired gas or saliva might return to lower or even undetectable levels. To prevent the patient from predicting when the notification will occur, the notification schedule will be unpredictable and can be programmed in an infinite number of permutations based on frequency, number of notifications per day, max/min time between notifications, time allowed to respond, etc. Further, the pattern of notifications will not repeat itself on subsequent days, further making the pattern unpredictable and undefeatable.
- Patient devices 10 , 36 may be programmed to be active during wake hours only or may include sleep hours as well.
- the hours of operation are programmable based on healthcare provider choice and patient need.
- One example would be to have the unit active from 6 am to 12 midnight every day.
- Another example would be to have the unit be normally active during the waking hours with frequent notifications at unpredictable times, and then revert to an alternative schedule during sleep hours where only one or two signals occur at night. This would provide a modicum of aversion to smoking at night by the patient in an attempt to defeat the system, yet would not dramatically disrupt sleep patterns.
- Another alternative would be to have the system active twenty-four hours per day, and night time failed test events (no response by patient) be considered as sleep events and not counted against the patient as positive for the undesirable behavior.
- a patient is enrolled in a smoking cessation program and self-reports a certain amount of smoking behavior (number of cigarettes smoked per day) upon entry into the program (baseline smoking behavior).
- the patient completes the enrollment process and initial counseling visit with a healthcare professional.
- the patient begins NRT and is provided with mobile patient device 10 programmed to function between 6 am and 12 midnight each day.
- the signaling unit prompts the patient approximately twenty times each day to follow the provided instructions for how to perform exhalation testing with the detector unit.
- the detector unit may also provide displayed or audio instructions through the graphical user interface.
- the patient must comply within a predetermined time period (for example, within 3 minutes of notification) or else the event is considered a failure to respond. In the analysis of the data, this failure to respond can be treated as a positive smoking behavior event or can be ignored.
- the level of CO ppm
- All data is logged and stored in the detector or signaling unit (or uploaded real time or intermittently) until downloaded to a software analysis program. Further, the user interface may prompt the patient to enter additional information about lifestyle events that occur during the day (meals, activity, sex, alcohol consumption, stress, travel, etc.) that can then be temporally correlated with smoking behavior as detected by the exhaled gas to draw conclusions about trigger events for smoking behavior.
- the detector unit may scroll through a number of potential scenarios for selection by the patient (i.e., did you have a meal in the last thirty minutes, did you have a drink in the last thirty minutes).
- the healthcare provider downloads the data and uses a software program to analyze the data.
- the data was uploaded in advance of the visit obviating the need for download.
- a print out is provided which shows the daily notification times and the associated CO levels, as well as the missed or possibly faked responses.
- the analysis program is described further below, but there are several summary metrics which could be tracked to estimate the number of cigarettes smoked and the timing of peak substance in the bloodstream.
- Correlations are made between program interventions versus trends in smoking behavior over time. Correlations are also made between recorded lifestyle events and smoking behavior to allow improved counseling and drug therapy interventions.
- the printed analysis is provided to the patient for positive/negative feedback regarding their progress and response to therapy. Each week, this process is repeated, progress towards the goal of smoking cessation is tracked and medical therapy is adjusted according to the objective data in an optimized manner.
- Analysis of the data can be performed in many different ways in various alternative embodiments. Once the data is uploaded or downloaded, many different metrics can be summarized and analyzed. Each day of use may have, for example, twenty test points for analysis. The timing and number of test points is variable and can be preprogrammed according to healthcare professional recommendation and needs. Each test point will have a yes/no, binary value, as well as a quantitative value. The yes/no value may have a role in determining if the patient is smoking “at all” and, if any tests are “yes”, may provide some insight into how often during the day the patient is smoking. The quantitative value for each test interval, if positive, may provide additional information about how often the patient is smoking and trends towards abstinence.
- Another software analysis feature involves an interactive program that the patient engages within the interval between cessation program visits (for example, between biweekly program visits). Such a patient-interface could be used by persons who independently utilize this cessation system outside of a smoking cessation program. While the devices would be similar to the previously disclosed detector and signaling units, such an embodiment may include means by which the patient can upload the data on a regular basis to a local or remote source (or both) and follow their data on a regular basis for trends and feedback. As the data is uploaded and analyzed, the data is added to previously uploaded data and can be viewed by the patient and healthcare provider and other authorized persons. The data can be displayed for any party in the same manner as it is displayed for the healthcare professional.
- unique, patient-friendly interactive displays can be provided for the patient so that they can track and observe their smoking behavior in a number of ways, including total number of days in the program, baseline smoking behavior compared to current smoking behavior, number of cigarettes avoided in last period of time, number of hours, days, months, and years of lifetime saved, time to goal of smoking cessation, daily results, weekly results, progress towards goal displayed numerically or graphically.
- Other metrics can also be tracked and correlated with smoking behavior results, such a blood pressure, heart rate, body weight, quality of life testing, stress level questionnaire results, and others.
- prompts can be provided to the patient that are positive reinforcement about good behavior and improvements, alterations that may be made to drug therapy, observations about lifestyle events that may be precipitating smoking behavior, etc. Additionally, the patient can observe within the analysis program which lifestyle events may be impacting daily smoking behavior. Avoidance of these situations can then ensue.
- a series of questions could be levied each day (or more or less frequently) to the patient, which could be standardized or could be prompted by certain changes (improvement or worsening) in smoking behavior. For example, a patient may be asked at the end of each day to log in the analysis program the number of cigarettes smoked, blood pressure measurement, heart rate, quality of life scale questions, significant life event, etc. Results of these queries can be tracked overtime with the smoking behavior objective readings from the CO monitoring data. Such linkage of patient volunteered data as well as objective data and therapeutic intervention data are helpful for the patient and healthcare professional to tailor therapy optimally.
- Such other examples include: oral placement of certain substances, with specific examples including but not limited to placing chewing tobacco and snuff in the oral cavity, transdermal absorption of certain substances, with specific examples including but not limited to application on the skin of certain creams, ointments, gels, patches or other products that contain drugs of abuse, such as narcotics, LSD, GHB, Rohypnol, ketamine, methamphetamine, PCP/phencyclidine, anabolic steroids, and secreted or exhaled metabolites of said substances, and nasal sniffing of drugs or substances of abuse, which includes but is not limited to sniffing cocaine.
- drugs of abuse such as narcotics, LSD, GHB, Rohypnol, ketamine, methamphetamine, PCP/phencyclidine, anabolic steroids, and secreted or exhaled metabolites of said substances
- nasal sniffing of drugs or substances of abuse which includes but is not limited to sniffing cocaine.
- detector unit 12 may differ somewhat in design only to account for different marker substances that are required for testing or different testing methodology necessitated by the different markers associated with particular undesired behaviors.
- a patient participating in a formal cessation program may take advantage of the assistive devices, methods and systems disclosed herein as adjuncts to the cessation program.
- the patient may be independently self-motivated and thus beneficially utilize the assistive devices, methods and systems for quitting the undesired behavior unilaterally, outside of a formal cessation program.
- devices, systems and methods disclosed herein may be readily adapted to data collection and in particular to collection of reliable and verifiable data for studies related to undesired behaviors for which the present invention is well suited to test. Such studies may be accomplished with virtually no modification to the underlying device or methods except that where treatment was not included there would not necessarily be a need for updating of the test protocol or treatment protocol based on user inputs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 12/910,371 filed Oct. 22, 2010 (now U.S. Pat. No. 9,675,275), which claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 61/254,685, filed Oct. 24, 2009, and titled Extracorporeal Devices and Method for Intermittent Signaling and Prompting of Patient Self-Testing for Substances, each of which is incorporated by reference herein in its entirety.
- The present invention generally relates to the field of behavioral modification. In particular, exemplary embodiments of the present invention are directed to extracorporeal devices, systems and methods for facilitating cessation of undesired behaviors.
- Certain persons may engage in certain undesirable activities that have significant negative acute and/or long-term health, social, and safety implications for the person and for other associated persons. In some cases, the person may wish to quit this behavior. Often, the person's family, friends, and/or healthcare providers are also engaging with the person in an attempt to have them quit the behavior. Associated persons may also be negatively impacted by the behavior, socially, financially, and from a health perspective. Such behavioral modification or cessation attempts to terminate the undesirable behavior may be formal and administered by healthcare professionals, or the person may take their own personalized approach to cessation.
- An example of such a behavioral modification program is a formal multi-modality smoking cessation program that utilizes counseling and drug therapy to achieve the end goal of abstinence from smoking. Drug therapy typically includes one or more of: nicotine replacement therapy, welbutryn, varenicline, and other drugs. Alcohol cessation programs, by comparison, may include similar approaches with counseling and drug interventions targeted specifically to achieve abstinence from alcohol use and abuse.
- In a typical multi-modality smoking cessation program, participants are asked to voluntarily and honestly report on their smoking behavior before and during therapy. For example, the patient's baseline smoking behavior is measured according to the patient's own voluntary report and is based solely on their recall (i.e., patient states that they average forty cigarettes per day prior to entering program). The patient may also be asked to provide a blood sample at the clinic or hospital location to test for substances associated with smoking behavior, such as hemoglobin bound to carbon monoxide. Alternatively, the patient may be asked to exhale into a device at the clinic or hospital location to detect carbon monoxide levels in the exhaled gas from the lungs. Such tests would be performed on location and observed by the health care provider, and such tests may require processing by a professional laboratory. Based on the values of carbon monoxide or other substances at this specific point in time, a gross estimate of smoking behavior may be made by the health care professional. Limitations of such testing are that it is made at a single point in time and likely does not fully and accurately reflect the true behavior of the patient at multiple time points before entering the program. The patient may alter their behavior, for example, for days prior to testing thus making the test result less relevant and accurate.
- At each visit during a patient's cessation program participation, the patient's interval smoking behavior since the previous visit is quantified by patient voluntary reporting (recollection, diary, etc.). For example, if the patient is seen weekly, they will report on their smoking behavior for the prior seven days. Typically, the patient keeps a diary or smoking log during each interval in which daily entries are made regarding the number of cigarettes smoked and certain lifestyle events that occur in conjunction with smoking behavior. This methodology relies on compliance and full disclosure by the smoker, as well as a commitment to record the data every day.
- Clinical trials have shown that patients often fail to disclose their true smoking behavior when queried in this manner, grossly under-reporting the amount of smoking that takes place or forgetting certain lifestyle events that are associated with smoking. These limitations in reporting impair the effectiveness of the program. Further, blood tests or exhaled carbon monoxide breath tests may be performed on the spot at these weekly or biweekly visits, to detect substances associated with smoking. Unfortunately, such predictable and infrequent testing gives the patient the opportunity to abstain for hours or longer prior to the visit to avoid detection of smoking behavior or to lessen the positivity of the test. Such behavior results in collecting physiological data that erroneously suggests that smoking has stopped or diminished. For example, if a patient has a bi-weekly 3 pm clinic visit on Mondays, they may abstain from smoking after 9 am on the day of the visit so that their blood and exhaled breath levels of carbon monoxide decline or normalize in time for the test. Further, such spot testing by the clinic is infrequent and does not accurately represent patient behavior during non-clinic days. Due to these significant limitations, counseling and drug therapy cannot be accurately and effectively tailored to optimize patient outcomes. If healthcare professionals do not have accurate information regarding true patient behavior, for example, the efficacy of the cessation program will be severely impaired. This is one reason why failures of smoking cessation programs, as well as other behavioral cessation programs, are so high and recidivism almost guaranteed. Given the currently limited options for objectively determining a patient's smoking behavior, (or other behaviors) a more objective and accurate means of determining a patient's behavior is needed.
- In one exemplary embodiment of the present invention, a method for facilitating cessation of undesired behavior in a patient includes steps such as configuring a patient device with a predetermined test protocol including patient test prompts, prompting the patient in accordance with the predetermined test protocol to provide at least one biological input to the patient device, the biological input being correlated to the undesired behavior, analyzing the patient biological input to the patient device, generating a machine readable data set representative of the patient input based on the analyzing, associating the data set with a specific patient biological input, evaluating the predetermined test protocol based on the data set, and altering or maintaining the predetermined test protocol based on the evaluation. In certain embodiments, such a method may also include steps of determining whether the patient properly provided a biological input in response to the prompting, and re-prompting the patient to provide the at least one biological input when the determining result is negative.
- Other aspects of exemplary embodiments may include remotely reconfiguring the test protocol in the patient device through a communications network, prompting the patient to input requested information to the patient device through a user interface, and associating the requested information with the data set associated with a specific patient's biological input. Additionally, the evaluating may be based on the requested information associated with the data set.
- In further exemplary embodiments, methods according to the present invention may include transmitting the data set and associated requested information to a health care provider device. Other optional steps may include communicating with the patient device through a network, and prompting the patient to provide at least one biological input outside of the predetermined test protocol. In order to arrive at a test protocol, exemplary embodiments may also include collecting data related to the patient undesired behavior, and analyzing the patient behavior data to determine the predetermined test protocol.
- In another exemplary embodiment of the present invention, system for facilitating cessation of undesired behavior in a patient includes a patient device or PD and a health care provider device or HCPD that are configured to communicate with one another through a network or other known means of data transfer. The PD may be configured and dimensioned to be carried by the patient, may include a PD user interface, a test element configured to receive a biological input from the patient and output information representative of the content of the biological input, a PD storage module containing instructions for various functions including for a predetermined test protocol, and a PD execution module communicating with the user interface, the test element and the storage module, the PD execution module configured to execute instructions contained in said PD storage module.
- The predetermined test protocol instructions may, for example, include prompting the patient through the user interface to provide a biological input to the test element at selected intervals, determining the completeness of a biological input, and providing additional patient prompts based on the completeness determination.
- In such exemplary embodiments, an HCPD may be configured to be accessed by a health care provider, and include an HCPD user interface, an HCPD storage module containing certain instructions and an HCPD execution module communicating with the user interface and storage module, the execution module configured to execute instructions contained in the HCPD storage module.
- Instructions stored in the HCPD storage module may include instructions for displaying and manipulating information representative of the content of the biological input, and revising the predetermined test protocol based on at least one of user input and the information representative of the content of the biological input.
- In certain other exemplary embodiments instructions for executing some functions may be stored in either the PD or HCPD storage modules and executed by the associated execution modules as appropriate. Examples of such instructions may include instructions for generating a machine readable data set based on the test element output information, and for associating the data set with a specific patient biological input, or instructions for causing the patient device to prompt the patient to input requested information to the patient device through the PD user input and for associating the requested information with a data set associated with a specific patient biological input.
- In further exemplary embodiments, the patient device may further include an identification device for acquiring patient identifying information correlated to a biological input. Such an identification device may communicate with the storage module and execution module for associating the acquired identifying information with the correlated biological input and storing the associated identifying information. The system may also permit receiving unprompted patient input through the PD user input and then associating the unprompted input with a biological input based on a predetermined algorithm.
- In another exemplary embodiment of the present invention, an apparatus for use in connection with facilitating cessation of undesired behavior in a patient, may include at least one housing configured and dimensioned to be carried by the patient, a user interface disposed in the at least one housing, a test element disposed in the at least one housing, the test element being configured to receive a biological input from the patient and output information representative of the content of the biological input, a storage module containing instructions related to the operation of the apparatus, and an execution module communicating with the user interface, the test element and the storage module.
- Exemplary instructions contained in the storage model, which may be executed by the execution module, may include instructions for executing a predetermined test protocol, b) generating user readable indicator based on the test element output and displaying the output on the user interface, associating the user readable indicator with a specific biological input, associating the requested information with a specific user readable indicator associated with a specific patient biological input, and storing test result information including the user readable indicator and associated requested information in the storage module. The predetermined test protocol instructions may include steps of prompting the patient through the user interface to provide a biological input to the test element at selected intervals, determining the completeness of a biological input, providing additional patient biological input prompts based on the completeness determination, and prompting the patient to input requested information through the user interface.
- In some exemplary embodiments, the apparatus may be configured to communicate through a network for transfer of the test result information.
- In yet another exemplary embodiment of the present invention, a method for collecting and confirming patient participation in select behaviors, may include steps such as configuring a patient device with a predetermined test protocol including patient test prompts, prompting the patient in accordance with the predetermined test protocol to provide at least one biological input to the patient device, the biological input being correlated to the select behavior, determining whether the patient properly provided a biological input in response to the prompting, re-prompting the patient to provide the at least one biological input when the determining result is negative, analyzing the patient biological input to the patient device, generating a machine readable data set representative of the patient input based on the analyzing, associating the data set with a specific patient biological input, prompting the patient to input requested information to the patient device through a user interface, associating the requested information with the data set associated with a specific patient biological input, evaluating the predetermined test protocol based on the data set and the requested information associated with the data set.
- For the purpose of illustrating the invention, the drawings show aspects of one or more embodiments of the invention. However, it should be understood that the present invention is not limited to the precise arrangements and instrumentalities shown in the drawings, wherein:
-
FIG. 1 is a block diagram illustrating a patient monitoring device according to an exemplary embodiment of the present invention. -
FIG. 2 is a diagram illustrating a system according to an exemplary embodiment of the present invention. -
FIG. 3 is a flow chart illustrating a method according to an exemplary embodiment of the present invention. - Embodiments of the present invention provide devices, methods and systems capable of prompting a patient to perform self-testing for undesired behaviors, objectively analyzing the test results, logging the data to a local or central storage unit, and providing a comprehensive interface for the patient and healthcare professional to analyze and observe results and correlate these results with progress within a cessation program. Such self-testing may be according to a protocol that is monitored and altered in real time to adapt to specific circumstances of the patient's needs. While exemplary embodiments of the present invention are described in more detail in connection with smoking cessation, and to some extent alcohol cessation, it will be appreciated by those skilled in the art that the devices, methods and systems taught herein are generally applicable to facilitating behavior modification with respect to any number of undesired behaviors for which markers are present in the patient's breath or saliva.
- A number of undesirable behaviors that involve smoking of one or more substances, oral ingestion of one or more substances, oral placement of one or more substances, transdermal absorption of one or more substances, nasal sniffing of one or more substances, and other methods of absorbing one or more substances result in the subsequent presence of one or more of the substances in the exhaled breath. The presence of a unique substance or substances in the exhaled breath can be used as a marker for the specific undesirable behavior and intermittent testing of the exhaled breath for this substance(s) can quantify the occurrence of the undesirable behavior.
- Such substances may be detected in the exhaled breath due to one or more of the following mechanisms: 1) the substance was previously absorbed into the body and bloodstream and is then released from the bloodstream into the pulmonary airspace for exhalation, 2) the substance was very recently inhaled into the pulmonary dead space (non-absorbing portion of inhaled air) and is being exhaled acutely therefore not requiring a blood level of the substance to be present, 3) the substance is present in the oral cavity mucous and epithelial surface layers and certain portions volatilized into the exhaled breath, 4) the substance was previously absorbed into the body and bloodstream and is then released from salivary glands into the oral cavity in the saliva and then volatilized into the exhaled breath, and/or 5) the substance was exhaled previously and a portion of the substance was retained within the oral cavity mucous and epithelial surface layers and certain portions subsequently volatilized into the exhaled breath.
- One alternative to intermittently testing the exhaled breath to detect one or more substances associated with an undesirable behavior is to intermittently test saliva for one or more substances associated with an undesirable behavior, as these substances as disclosed above often reside in the oral cavity via secretion within the saliva from the bloodstream or accumulation within the oral cavity mucous, saliva, and epithelial lining due to ingestion or exhalation residues.
- In the specific example of smoking cessation, high quality objective data collected in an improved manner could be used by the healthcare professional to adjust therapy (i.e., nicotine replacement therapy, other drug therapy, counseling, etc.) to achieve a better outcome, to provide real-time or delayed positive and negative feedback to the patient, to determine success or failure of the cessation program, and to provide long-term maintenance of cessation after successfully quitting the behavior (avoidance of recidivism). For example, if smoking behavior remained unchanged after initiating counseling and a trial of nicotine replacement therapy (NRT), the dose of the NRT could be immediately increased and/or other therapies could be added with this approach. Likewise, as smoking behavior began to improve as evidenced by objective signs of decreased frequency of smoking, the various therapies could be titrated downward and ultimately discontinued.
- An exemplary embodiment of a patient monitoring device according to the present invention is illustrated in
FIG. 1 . In this exemplary embodiment, patient device 10 includes two main components:extra-corporeal detector unit 12 containing at least one test element and signaling unit 16. The components may be combined into a single unit or may be separated physically. Other embodiments may include additional components and these components may be combined or separate as well. -
Extra-corporeal detector unit 12 includes at least one test element that is capable of detecting a substance in a biological input from the patient that is indicative of recent targeted behavior. The detector analyzes the biological input from the patient, such as expired gas from the lungs or saliva, and in at least one embodiment logs the date and time of day, quantifies the presence of the targeted substance(s), and then stores the data for future analysis and/or sends the data to a remote location for analysis.Detector unit 12 thus may include a processor, memory anduser interface 14 as appropriate for its specific functions. The user interface may include data inputs such as a touch screen, keyboard or pointer. - Detector units may be specifically configured by person of ordinary skill in the art for detection of specific marker substances related to targeted behaviors as described herein. Examples of substances detected related to smoking include but are not limited to carbon monoxide, nitrogen oxides, ammonia, arsenic, nicotine, acetone, acetaldehyde, formaldehyde, hydrogen cyanide, isoprene, methyl ethyl ketone, benzene, toluene, phenol, and acrylonitrile. Sensor technologies for detecting alcohol in the exhaled breath include infrared spectrophotometer technology, electrochemical fuel cell technology, or a combination of the two. Smaller portable units well suited for use in embodiments of the invention may be based on electrochemical fuel cell analysis or “Taguchi cell” sensors.
- One example of a suitable detector unit for determining the presence of alcohol in the breath is described in U.S. Pat. No. 7,797,982, entitled “Personal Breathalyzer Having Digital Circuitry.” Another example of detector units that may be configured to determine the presence of a variety of substances is disclosed in U.S. Pat. No. 7,421,882, entitled “Breath-based Sensors for Non-invasive Molecular Detection.” U.S. Pat. No. 7,525,093, entitled “Liquid or Gas Sensor and Method” discloses another sensor device that may be readily incorporated into embodiments of the present invention by persons of ordinary skill in the art. Each of the forgoing U.S. patents are incorporated by reference herein in their entirety.
-
Detector unit 12 may also be configured to recognize a unique characteristic of the patient, such as a fingerprint, retinal scan, voice label or other biometric identifier, in order to prevent, at least to a degree, having a surrogate respond to the signaling and test prompts to defeat the system. For this purpose, patient identification sub-unit 15 may be included indetector unit 12. Persons of ordinary skill in the art may configure identification sub-unit 15 as needed to include one or more of a fingerprint scanner, retinal scanner, voice analyzer, or face recognition as are known in the art. Examples of suitable identification sub-units are disclosed, for example in U.S. Pat. No. 7,716,383, entitled “Flash-interfaced Fingerprint Sensor,” and U.S. Patent Application Publication No. 2007/0005988, entitled “Multimodal Authentication,” each of which is incorporated by reference herein in their entirety. - Identification sub-unit 15 may also comprise a built in still or video camera, which would record a picture or video of the patient automatically as the biological input is provided to the test element. Regardless of the type of identification protocol used, the processor and memory in the detector unit will associate the identification with the specific biological input, for example by time reference, and may store that information along with other information regarding that specific biological input for later analysis.
- A patient may also attempt to defeat the detector by blowing into the detector with a pump, bladder, billows, or other device, for example, when testing exhaled breath. In the embodiment of saliva testing, a patient may attempt to substitute a “clean” liquid such as water. While no means will absolutely prevent an uncooperative and determined patient from these attempts, some means to defeat these attempts can be incorporated in to the system. For example, the detector unit may incorporate the capability of discerning between real and simulated breath delivery. In one exemplary embodiment this functionality may be incorporated by configuring
detector unit 12 to sense oxygen and carbon dioxide, as well as the maker substance (carbon monoxide, etc.). In this manner, the detector is able to confirm that the gas being analyzed is truly coming from expired breath, as expired breath has lower oxygen and much higher carbon dioxide than ambient air. In another embodiment, the detector unit may be additionally configured to detect enzymes naturally occurring in saliva so as to distinguish between saliva and other liquids. Basic biochemical tests are well known to persons skilled in the art for identifying such substances. - Signaling unit 16 may communicate with
detector unit 12 through an appropriate communication link 20 (for example, wired, WI-FI, Bluetooth, RF, or other means) as may be devised by a person of ordinary skill in the art based on the particular application. Signaling unit 16 may be integrated withdetector unit 12 in patient device 10 or may separate from the detector unit, but the units are synchronized and able to communicate real-time or at various intervals in order to correlate signaling and detector results. Thus, when physically separate fromdetector unit 12, signaling unit 16 may include its own processor, memory and graphical user interface 18, but when integrated withdetector unit 12 both units may share one of more of those subcomponents. Utilizing graphical user interface 18, signaling unit 16 prompts the patient to blow into the detector unit at various times of the day, and/or prompts the patient to test their saliva or other body fluid as appropriate for the specific detector unit input. Together, memory fordetector unit 12 and signaling unit 16 will contain instructions appropriate for operation of the patient device in accordance with the various method embodiments described herein. - In some circumstances, a prompt to test may have to be ignored for reasons not considered noncompliant due to the patient being engaged in an activity that prevents testing, such as exercise, work, driving, etc. A means by which to delay testing in response to a prompt, such as “snooze button” 19 may be incorporated. For example, if a patient is driving a vehicle, they may push button 19 to activate a preset interval until the test is again requested. A certain number of delays may be permitted each day, with this number being set by the provider or patient in the program.
- Signaling unit 16 may also include means permitting the patient to input information that the patient believes relevant to his or her condition without prompting. Such information may, for example, include information about the patient's state of mind, that is feeling stressed or anxious. Such unprompted information could then be correlated to a biological input based on a predetermined algorithm, such as being associated with the biological input that is closest in time to the unprompted input, or associated with the first biological input occurring after the unprompted input.
- In one exemplary embodiment of patient device 10, detector and signaling
units 12, 16 are combined and exist in an entirely portable configuration with battery power. Such embodiments may also be provided with network connection capability (WI-FI, wireless cell, RF, etc.) as described in greater detail below. For example, a PDA-like device that is able to both signal the patient as well as perform the expired gas analysis could be carried in the patient's pocket at all times and improve compliance by the patient by allowing them to respond immediately to notifications. - In yet another exemplary embodiment, wherein
detector unit 12 and signaling unit 16 are physically separate units, the signaling unit may be configured to be worn as a wristwatch or carried like a PDA. Likewise, the detector would be worn or carried, but separately. In any separate unit embodiment, the units are time synchronized or linked via awireless communication link 20 to allow analysis of the time dependent data (linking of the notification and exhalation events). - In the example of a combined unit or wirelessly (or wired) connected units, either the detector or the signaling unit could act as the storage entity for the data utilizing its own internal memory. Alternatively, either could act as the sending unit to upload the data to a remote source for live tracking of patient data as described in more detail below. Data could be uploaded immediately, intermittently or not at all. The data could also be downloaded from the storage media either by the patient or health care professional
- In a further exemplary embodiment, as illustrated in
FIG. 2 , system 30 includes mobile patient devices 10 (including integrated detector and signaling units) and/or standalone detector units 12 that communicate through network 32 with healthcare provider base station 34. Network 32 may comprise the Internet, a land-based or cellular telephone network or any other communications networks or combination of networks as appropriate for the particular patients and cessation program. Healthcare provider base station 34 may comprise a specially programmed personal computer in a doctor's office linked to communication network 32 through an appropriate communications buss or a specialized device including its own memory, processor and graphical user interface. Persons of ordinary skill in the art may configure and program base station 34 based on the teachings contained herein. - System 30 also may include fixed patient devices 36. Fixed patient devices may comprise substantially the same components as mobile patient devices 10 except that they are configured to be fixed at a particular location such as a patient's home, office or automobile. In addition, system 30 permits remote programming by the healthcare provider as appropriate for the particular patient and/or cessation program. An exemplary method for implantation of a cessation program utilizing system 30 is described in greater detail with reference to the flow chart of
FIG. 3 . - As illustrated in
FIG. 3 , system 30 may be preprogrammed to prompt the patient at specific times (step 40) and/or the healthcare provider (HCP) may randomly prompt the patient (step 42) when there is a concern that behavior is timed to avoid preprogrammed prompts. Alternatively the programmed prompts 40 may occur at random intervals as described in more detail below. For example, patient devices 10 may be programmed to be operational during prescribed hours (typically waking hours, for example from 6 am to 11 pm), although sleep hour function can be activated. The patient is prompted at various times throughout the day to exhale into the detector. The patient is instructed (step 44) with each prompt regarding how to properly and consistency perform the requested test. In one example of an algorithm for breath testing, the patient will take several full breaths in and out into the detector, followed by a deep test exhalation for the detector to analyze. A determination is then made (step 46) as to whether the patient has complied. Circumstances of non-compliance may also be determined (step 48). For example if device 10 determines that there was simply no attempt at compliance the patient may be re-instructed a set number of times (branch 50). However, after a predetermined number of re-instructions without compliance, the device simply may report a non-compliant episode (branch 52). Alternatively, if it is determined that the patient attempted to comply but compliance was incomplete (for example, does not exhale fully) then the test may be rejected and the patient instructed to repeat the test (branch 50). - When compliance is determined (branch 54), the sample is analyzed (step 56) according to the predetermined detector unit protocol. Marker substances, if present, may be quantified at each test interval if such analysis is included in the protocol. Each event may be reported (step 58), either in real time through network communications or via periodic downloads. To facilitate reporting and data logging, data regarding the qualitative (yes/no) values as well as the quantitative substance level may be stored within the detector in a memory unit such as a flash drive or disk. As is known in the art, such a storage medium may be used to transfer stored data to a health care provider device, thus providing communication to the patient device and health care provider device. Alternatively, as mentioned, the unit may upload the data live via a cell connection or local network. Such upload may occur intermittently or immediately. Disk space may be freed up upon confirmation of successful upload, as needed. Reported events are analyzed (step 60), for example by being categorized as either negative or positive for the substance of interest based on a pre-determined threshold for positivity, and therefore negative or positive for the smoking behavior. The threshold for positivity may be set at standard levels derived from the scientific literature or may be adjusted by the healthcare professional to the specific needs of the patient. Such adjustments may occur in real time based on data analysis and may include changes in the testing as well as prompting protocols.
- If the patient fails to respond (fails to blow into the unit) within a certain period of time after receiving the signal to respond (for example, within 3 minutes although the time interval allowable for testing may be set at any preferred value), the event is interpreted as a failure and flagged in the database. Data analysis can interpret failed tests as being positive for smoking behavior or may omit the value entirely. The analysis tool is capable of variably dealing with such failed signals for testing. If considered positive for a smoking behavior, a positive quantitative value may be assigned to that data point. Such a design prevents the patient from gaining a benefit (logging a negative data point) by ignoring a signal if they were engaging in smoking at the time of the signal to test.
- Programming necessary to implement the exemplary methodology illustrated in
FIG. 3 may exist entirely within software or firmware resident in patient device 10, divided betweendetector unit 12 and signaling unit 16 as appropriate for the particular configuration of the device. Alternatively, such programming may at least in part reside in a server or other source associated with base station 34, communicating with patient devices 10 and 36 and/ordetector unit 12 through communications network 32. - Regardless of the exact embodiment of the invention as a single unit (combined and integrated) or multiple units, an advantage of the present invention is that it may be specifically configured for individual patients so that the detector and signaling unit can be with the patient at all times. The patient is thus able to respond to a signaling notification within the allotted and permitted time interval (i.e., within about 2-10 minutes) at all times and may not use lack of availability as an excuse for noncompliance.
- In one exemplary embodiment, the patent prompts are programmed to be intermittent and of varying intervals, so as not to be predictable. The frequency of prompting can vary throughout the day, and the pattern can be unpredictable and non-repeating, thus preventing the patient from predicting when they will be notified to blow into the detector or test saliva. Alternatively, or additionally, the healthcare provider may initiate additional prompts through network 32 when in appropriate circumstances. This unpredictability and variability prevents the patient from modifying the timing of their smoking behavior in such a manner so as to avoid detection of the smoking behavior or to minimize the quantitative result of the test. Further, the number of signaling events per day can vary, for example on one day twenty signals may be delivered, while on the next day only twelve are delivered. Variability can be important, for example, if the signaling unit notified the patient every hour on the hour, the smoker could smoke three cigarettes immediately after the hour then avoid smoking for the remainder of the hour until prompted next. Presumably, during that hour-long interval of no smoking, the substance detected in expired gas or saliva might return to lower or even undetectable levels. To prevent the patient from predicting when the notification will occur, the notification schedule will be unpredictable and can be programmed in an infinite number of permutations based on frequency, number of notifications per day, max/min time between notifications, time allowed to respond, etc. Further, the pattern of notifications will not repeat itself on subsequent days, further making the pattern unpredictable and undefeatable.
- Patient devices 10, 36 according to embodiments of the invention may be programmed to be active during wake hours only or may include sleep hours as well. In the former, the hours of operation are programmable based on healthcare provider choice and patient need. One example would be to have the unit active from 6 am to 12 midnight every day. Another example would be to have the unit be normally active during the waking hours with frequent notifications at unpredictable times, and then revert to an alternative schedule during sleep hours where only one or two signals occur at night. This would provide a modicum of aversion to smoking at night by the patient in an attempt to defeat the system, yet would not dramatically disrupt sleep patterns. Another alternative would be to have the system active twenty-four hours per day, and night time failed test events (no response by patient) be considered as sleep events and not counted against the patient as positive for the undesirable behavior.
- The following is one example of a practical application of one embodiment of the invention. A patient is enrolled in a smoking cessation program and self-reports a certain amount of smoking behavior (number of cigarettes smoked per day) upon entry into the program (baseline smoking behavior). The patient completes the enrollment process and initial counseling visit with a healthcare professional. The patient begins NRT and is provided with mobile patient device 10 programmed to function between 6 am and 12 midnight each day. During the active daily interval, the signaling unit prompts the patient approximately twenty times each day to follow the provided instructions for how to perform exhalation testing with the detector unit. The detector unit may also provide displayed or audio instructions through the graphical user interface. The patient must comply within a predetermined time period (for example, within 3 minutes of notification) or else the event is considered a failure to respond. In the analysis of the data, this failure to respond can be treated as a positive smoking behavior event or can be ignored. In the example of carbon monoxide as the test substance, the level of CO (ppm) is recorded at each test instance. All data is logged and stored in the detector or signaling unit (or uploaded real time or intermittently) until downloaded to a software analysis program. Further, the user interface may prompt the patient to enter additional information about lifestyle events that occur during the day (meals, activity, sex, alcohol consumption, stress, travel, etc.) that can then be temporally correlated with smoking behavior as detected by the exhaled gas to draw conclusions about trigger events for smoking behavior. For example, after a test the detector unit may scroll through a number of potential scenarios for selection by the patient (i.e., did you have a meal in the last thirty minutes, did you have a drink in the last thirty minutes). If not uploaded automatically through a communications network, then at the one-week visit, the healthcare provider downloads the data and uses a software program to analyze the data. Alternatively, the data was uploaded in advance of the visit obviating the need for download. A print out is provided which shows the daily notification times and the associated CO levels, as well as the missed or possibly faked responses. The analysis program is described further below, but there are several summary metrics which could be tracked to estimate the number of cigarettes smoked and the timing of peak substance in the bloodstream. Correlations are made between program interventions versus trends in smoking behavior over time. Correlations are also made between recorded lifestyle events and smoking behavior to allow improved counseling and drug therapy interventions. The printed analysis is provided to the patient for positive/negative feedback regarding their progress and response to therapy. Each week, this process is repeated, progress towards the goal of smoking cessation is tracked and medical therapy is adjusted according to the objective data in an optimized manner.
- Analysis of the data can be performed in many different ways in various alternative embodiments. Once the data is uploaded or downloaded, many different metrics can be summarized and analyzed. Each day of use may have, for example, twenty test points for analysis. The timing and number of test points is variable and can be preprogrammed according to healthcare professional recommendation and needs. Each test point will have a yes/no, binary value, as well as a quantitative value. The yes/no value may have a role in determining if the patient is smoking “at all” and, if any tests are “yes”, may provide some insight into how often during the day the patient is smoking. The quantitative value for each test interval, if positive, may provide additional information about how often the patient is smoking and trends towards abstinence. Also these trends can provide information about peaks of smoking during each day and week. CO levels in expired gas, for example, peak immediately after smoking a cigarette or series of cigarettes, and then gradually decline over time. A time vs. CO level could be plotted and a predictive algorithm created to estimate the number of cigarettes and time of smoking per day for each patient. A time vs. CO level plot for each test period (day, week, month, year) provides significant information to the healthcare provider regarding patient progress in a longer term program and allows alteration of therapy in an objective manner. Further, on the time vs. CO plot, data regarding administration of medication, changes in medication regimens over time, counseling interventions, etc. can be annotated and used to track effect of each intervention and dose change. Such data analysis functionality may be incorporated into patient devices 10, 36, or may reside in healthcare provider base station 34.
- Another software analysis feature involves an interactive program that the patient engages within the interval between cessation program visits (for example, between biweekly program visits). Such a patient-interface could be used by persons who independently utilize this cessation system outside of a smoking cessation program. While the devices would be similar to the previously disclosed detector and signaling units, such an embodiment may include means by which the patient can upload the data on a regular basis to a local or remote source (or both) and follow their data on a regular basis for trends and feedback. As the data is uploaded and analyzed, the data is added to previously uploaded data and can be viewed by the patient and healthcare provider and other authorized persons. The data can be displayed for any party in the same manner as it is displayed for the healthcare professional. Alternatively, unique, patient-friendly interactive displays can be provided for the patient so that they can track and observe their smoking behavior in a number of ways, including total number of days in the program, baseline smoking behavior compared to current smoking behavior, number of cigarettes avoided in last period of time, number of hours, days, months, and years of lifetime saved, time to goal of smoking cessation, daily results, weekly results, progress towards goal displayed numerically or graphically. Other metrics can also be tracked and correlated with smoking behavior results, such a blood pressure, heart rate, body weight, quality of life testing, stress level questionnaire results, and others. If viewed simultaneously by the qualified health care professional, prompts can be provided to the patient that are positive reinforcement about good behavior and improvements, alterations that may be made to drug therapy, observations about lifestyle events that may be precipitating smoking behavior, etc. Additionally, the patient can observe within the analysis program which lifestyle events may be impacting daily smoking behavior. Avoidance of these situations can then ensue.
- In such a patient-centric interactive program, a series of questions could be levied each day (or more or less frequently) to the patient, which could be standardized or could be prompted by certain changes (improvement or worsening) in smoking behavior. For example, a patient may be asked at the end of each day to log in the analysis program the number of cigarettes smoked, blood pressure measurement, heart rate, quality of life scale questions, significant life event, etc. Results of these queries can be tracked overtime with the smoking behavior objective readings from the CO monitoring data. Such linkage of patient volunteered data as well as objective data and therapeutic intervention data are helpful for the patient and healthcare professional to tailor therapy optimally.
- While exemplary embodiments of the invention are described above with a focus on smoking behaviors, examples of which include but are not limited to smoking of tobacco via cigarettes, pipes, cigars, and water pipes, and smoking of illegal products such as marijuana, cocaine, heroin, and alcohol related behaviors, it will be immediately apparent to those skilled in the art that the teachings of the present invention are equally applicable to any number of other undesired behaviors for which markers are present in the breath and/or saliva. Such other examples include: oral placement of certain substances, with specific examples including but not limited to placing chewing tobacco and snuff in the oral cavity, transdermal absorption of certain substances, with specific examples including but not limited to application on the skin of certain creams, ointments, gels, patches or other products that contain drugs of abuse, such as narcotics, LSD, GHB, Rohypnol, ketamine, methamphetamine, PCP/phencyclidine, anabolic steroids, and secreted or exhaled metabolites of said substances, and nasal sniffing of drugs or substances of abuse, which includes but is not limited to sniffing cocaine. In general, the basic configuration of patient devices 10, 36, as well as the prompting, self-testing, data logging, feedback and other steps and methods as disclosed herein will be similar as between the different behaviors that are being addressed. However,
detector unit 12 may differ somewhat in design only to account for different marker substances that are required for testing or different testing methodology necessitated by the different markers associated with particular undesired behaviors. - It will also be appreciated by persons of ordinary skill in the art that a patient participating in a formal cessation program may take advantage of the assistive devices, methods and systems disclosed herein as adjuncts to the cessation program. However, in alternative embodiments, it will be equally appreciated that the patient may be independently self-motivated and thus beneficially utilize the assistive devices, methods and systems for quitting the undesired behavior unilaterally, outside of a formal cessation program.
- In further exemplary embodiments of the present invention, devices, systems and methods disclosed herein may be readily adapted to data collection and in particular to collection of reliable and verifiable data for studies related to undesired behaviors for which the present invention is well suited to test. Such studies may be accomplished with virtually no modification to the underlying device or methods except that where treatment was not included there would not necessarily be a need for updating of the test protocol or treatment protocol based on user inputs.
- Exemplary embodiments have been disclosed above and illustrated in the accompanying drawings. It will be understood by those skilled in the art that various changes, omissions and additions may be made to that which is specifically disclosed herein without departing from the spirit and scope of the present invention.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/619,109 US20170319105A1 (en) | 2009-10-24 | 2017-06-09 | Systems and methods for quantification of, and prediction of smoking behavior |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25468509P | 2009-10-24 | 2009-10-24 | |
US12/910,371 US9675275B2 (en) | 2009-10-24 | 2010-10-22 | Extracorporeal devices and methods for facilitating cessation of undesired behaviors |
US15/619,109 US20170319105A1 (en) | 2009-10-24 | 2017-06-09 | Systems and methods for quantification of, and prediction of smoking behavior |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/910,371 Continuation US9675275B2 (en) | 2009-10-24 | 2010-10-22 | Extracorporeal devices and methods for facilitating cessation of undesired behaviors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170319105A1 true US20170319105A1 (en) | 2017-11-09 |
Family
ID=44816366
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/910,371 Active 2032-03-28 US9675275B2 (en) | 2009-10-24 | 2010-10-22 | Extracorporeal devices and methods for facilitating cessation of undesired behaviors |
US15/619,109 Pending US20170319105A1 (en) | 2009-10-24 | 2017-06-09 | Systems and methods for quantification of, and prediction of smoking behavior |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/910,371 Active 2032-03-28 US9675275B2 (en) | 2009-10-24 | 2010-10-22 | Extracorporeal devices and methods for facilitating cessation of undesired behaviors |
Country Status (1)
Country | Link |
---|---|
US (2) | US9675275B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10306922B2 (en) | 2015-04-07 | 2019-06-04 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US10335032B2 (en) | 2017-10-10 | 2019-07-02 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US11257583B2 (en) | 2019-12-30 | 2022-02-22 | Carrot, Inc. | Systems and methods for assisting individuals in a behavioral-change program |
US11653878B2 (en) | 2009-10-24 | 2023-05-23 | Pivot Health Technologies Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005006988A1 (en) | 2003-06-19 | 2005-01-27 | Everest Biomedical Instruments | Breath end-tidal gas monitor |
US20160345631A1 (en) | 2005-07-19 | 2016-12-01 | James Monsees | Portable devices for generating an inhalable vapor |
US8814804B2 (en) | 2010-12-13 | 2014-08-26 | Iph, Llc | Interactive blood-alcohol content tester |
WO2013096695A2 (en) | 2011-12-21 | 2013-06-27 | Capnia, Inc. | Collection and analysis of a volume of exhaled gas with compensation for the frequency of a breathing parameter |
US10679309B2 (en) | 2011-12-30 | 2020-06-09 | Elwha Llc | Evidence-based healthcare information management protocols |
US10517530B2 (en) * | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
WO2014110181A1 (en) * | 2013-01-08 | 2014-07-17 | Capnia, Inc. | Breath selection for analysis |
AU2014216297A1 (en) | 2013-02-12 | 2015-09-17 | Capnia, Inc. | Sampling and storage registry device for breath gas analysis |
US20140272844A1 (en) * | 2013-03-15 | 2014-09-18 | Koninklijke Philips N.V. | Method for increasing the likelihood to induce behavior change in a lifestyle management program |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US11191449B2 (en) | 2013-08-30 | 2021-12-07 | Capnia, Inc. | Neonatal carbon dioxide measurement system |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
PT3504991T (en) | 2013-12-23 | 2021-03-01 | Juul Labs Int Inc | Vaporization device systems and methods |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
CA2938739C (en) * | 2014-02-07 | 2022-08-30 | Fred Hutchinson Cancer Research Center | Methods, systems, apparatus and software for use in acceptance and commitment therapy |
EP2946722A1 (en) * | 2014-05-20 | 2015-11-25 | Sensirion AG | Portable electronic device for breath sampling |
US20160219931A1 (en) * | 2015-01-30 | 2016-08-04 | Suraaj Doshi | System and Apparatus to Effect Behavioral Change |
EP3291169A4 (en) | 2015-05-01 | 2018-10-17 | CureApp, Inc. | Program, device, system, and method for patients who quit smoking |
EP3419443A4 (en) | 2016-02-11 | 2019-11-20 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
WO2017139595A1 (en) | 2016-02-11 | 2017-08-17 | Pax Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US20170301255A1 (en) * | 2016-04-14 | 2017-10-19 | Motiv8 Technologies, Inc. | Behavior change system |
US11521736B1 (en) | 2016-06-13 | 2022-12-06 | DynamiCare Health, Inc. | System and method for encouraging therapeutic psychosocial activity |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070072156A1 (en) * | 2005-08-05 | 2007-03-29 | Abk Ventures | Lifestyle coach behavior modification system |
WO2008006150A1 (en) * | 2006-07-11 | 2008-01-17 | Citech Research Ip Pty Ltd | Bio-activity data capture and transmission |
US20110270053A1 (en) * | 2004-05-28 | 2011-11-03 | David Scott Utley | Intra-Oral Detector and System for Modification of Undesired Behaviors and Methods Thereof |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA962021A (en) | 1970-05-21 | 1975-02-04 | Robert W. Gore | Porous products and process therefor |
US4220142A (en) | 1977-09-01 | 1980-09-02 | Raymond C. Rosen | Behavioral shaping device for eliminating nocturnal sounds |
JPS5594626A (en) | 1979-01-12 | 1980-07-18 | Hitachi Ltd | Absorbing liquid for carbon monoxide |
US4246913A (en) | 1979-04-02 | 1981-01-27 | Henry R. Harrison | Apparatus for reducing the desire to smoke |
US4585417A (en) | 1979-12-14 | 1986-04-29 | Coors Porcelain Company | Dental appliance and method of manufacture |
US4629424A (en) | 1984-08-30 | 1986-12-16 | Integrated Ionics, Inc. | Intraoral ambient sensing device |
US4609349A (en) | 1984-09-24 | 1986-09-02 | Cain Steve B | Active removable orthodontic appliance and method of straightening teeth |
US4996161A (en) * | 1987-10-16 | 1991-02-26 | Guardian Technologies, Inc. | Breath alcohol testing system |
US4971558A (en) | 1988-03-30 | 1990-11-20 | Board Of Regents Of The University Of Oklahoma | Porcelain inlay formed directly in a cavity and method for making same |
US4992049A (en) | 1988-05-12 | 1991-02-12 | Bernard Weissman | Method for applying a veneer facing to teeth |
US4904520A (en) | 1988-10-17 | 1990-02-27 | Hercules Incorporated | Gas-permeable, liquid-impermeable nonwoven material |
EP0384504A1 (en) | 1989-02-24 | 1990-08-29 | Duphar International Research B.V | Detection strip for detecting and identifying chemical air contaminants, and portable detection kit comprising said strips |
US5565152A (en) | 1989-03-23 | 1996-10-15 | Sandvik Ab | Method of making artificial tooth veneer |
NO168921C (en) | 1989-07-31 | 1992-04-22 | Svein Knudsen | SMOKE-FREE Cigarette replacement for use in smoking cessation OR FOR USE IN SMOKE-FREE ENVIRONMENTS |
JPH0433647A (en) | 1990-05-30 | 1992-02-05 | Shigeru Saito | Artificial tooth root |
US5063164A (en) | 1990-06-29 | 1991-11-05 | Quantum Group, Inc. | Biomimetic sensor that simulates human response to airborne toxins |
CA2072040C (en) | 1992-06-23 | 2002-06-11 | Charles Borg | Method and device to facilitate the cognitive development of alternative response behaviour |
US5829971A (en) | 1994-04-04 | 1998-11-03 | Razdolsky; Yan | Osteodistraction device for use in mandibular distraction osteogenesis and a method of making the device |
US5618493A (en) | 1994-08-29 | 1997-04-08 | Quantum Group, Inc. | Photon absorbing bioderived organometallic carbon monoxide sensors |
US6340588B1 (en) | 1995-04-25 | 2002-01-22 | Discovery Partners International, Inc. | Matrices with memories |
US5841021A (en) | 1995-09-05 | 1998-11-24 | De Castro; Emory S. | Solid state gas sensor and filter assembly |
US6018673A (en) | 1996-10-10 | 2000-01-25 | Nellcor Puritan Bennett Incorporated | Motion compatible sensor for non-invasive optical blood analysis |
US6039688A (en) * | 1996-11-01 | 2000-03-21 | Salus Media Inc. | Therapeutic behavior modification program, compliance monitoring and feedback system |
US6397093B1 (en) * | 1996-12-05 | 2002-05-28 | Essential Medical Devices, Inc. | Non-invasive carboxyhemoglobin analyzer |
US5908301A (en) * | 1996-12-05 | 1999-06-01 | Lutz; Raymond | Method and device for modifying behavior |
US6093158A (en) | 1997-05-15 | 2000-07-25 | Morris; Donald E. | Systems for modifying behavioral disorders |
US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
US6730494B1 (en) | 1999-09-17 | 2004-05-04 | Guardian Angel Holdings, Inc. | Alcohol concentration test delivery system |
US6602469B1 (en) * | 1998-11-09 | 2003-08-05 | Lifestream Technologies, Inc. | Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system |
EP1135052A1 (en) | 1999-02-12 | 2001-09-26 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US6164278A (en) | 1999-02-25 | 2000-12-26 | Nissani; Moti | Taste-based approach to the prevention of teeth clenching and grinding |
TW456130B (en) * | 1999-04-23 | 2001-09-21 | Tanita Seisakusho Kk | Exhalation gaseous component gauge and a cellular phone equipped with function of measuring gaseous components |
US6567785B2 (en) * | 1999-06-19 | 2003-05-20 | John Richard Clendenon | Electronic behavior modification reminder system and method |
US20020177232A1 (en) * | 2001-05-23 | 2002-11-28 | Melker Richard J. | Method and apparatus for detecting illicit substances |
US20020127145A1 (en) * | 2000-01-06 | 2002-09-12 | Viken Der Ghazarian | RF breathalyzer |
US20010027384A1 (en) | 2000-03-01 | 2001-10-04 | Schulze Arthur E. | Wireless internet bio-telemetry monitoring system and method |
US6613001B1 (en) | 2000-08-14 | 2003-09-02 | Jeffrey B. Dworkin | Intraoral appliance, monitoring device and method of treating patient |
US20120191052A1 (en) | 2000-10-06 | 2012-07-26 | Ip Holdings, Inc. | Intelligent activated skin patch system |
US6607387B2 (en) | 2000-10-30 | 2003-08-19 | Healthetech, Inc. | Sensor system for diagnosing dental conditions |
US6663831B2 (en) * | 2001-04-04 | 2003-12-16 | Forefront Diagnostics, Inc. | “One-device” system for testing constituents in fluids |
US8174394B2 (en) * | 2001-04-11 | 2012-05-08 | Trutouch Technologies, Inc. | System for noninvasive determination of analytes in tissue |
US7044911B2 (en) * | 2001-06-29 | 2006-05-16 | Philometron, Inc. | Gateway platform for biological monitoring and delivery of therapeutic compounds |
US20030003113A1 (en) * | 2001-06-29 | 2003-01-02 | Lewandowski Leon J. | Individualized addiction cessation therapy |
US7054679B2 (en) | 2001-10-31 | 2006-05-30 | Robert Hirsh | Non-invasive method and device to monitor cardiac parameters |
IL148468A (en) * | 2002-03-03 | 2012-12-31 | Exalenz Bioscience Ltd | Breath collection system |
US20070168501A1 (en) | 2002-03-29 | 2007-07-19 | Cobb Nathan K | Method and system for delivering behavior modification information over a network |
US20040158194A1 (en) | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
US6748792B1 (en) * | 2003-03-07 | 2004-06-15 | Lifesafer Interlock, Inc. | Impairment detection and interlock system with tester identification |
US7311665B2 (en) | 2003-05-19 | 2007-12-25 | Alcohol Monitoring Systems, Inc. | Bio-information sensor monitoring system and method |
EP1658580A4 (en) * | 2003-08-27 | 2007-06-20 | John Thomas Flanagan | System and method for facilitating responsible behaviour |
US20050053523A1 (en) * | 2003-09-10 | 2005-03-10 | Oxyfresh Worldwide, Inc. | Cell phone alcohol detector |
US7661955B2 (en) | 2003-10-03 | 2010-02-16 | Joseph Da Cruz | Dental appliance |
GB2407165B (en) * | 2003-10-17 | 2008-04-30 | Micro Medical Ltd | Apparatus for measuring carbon monxide on a person's breath |
US20090253220A1 (en) | 2003-10-28 | 2009-10-08 | Sukanta Banerjee | Absorbing Biomolecules into Gel-Shell Beads |
US7451852B2 (en) * | 2003-10-31 | 2008-11-18 | Sherman Enterprises, Inc. | Vehicle sobriety interlock system with personal identification element |
US7408640B2 (en) | 2003-11-05 | 2008-08-05 | The United States Of America As Represented By The Secretary Of The Navy | Fluorescence polarization instruments and methods for detection of exposure to biological materials by fluorescence polarization immunoassay of saliva, oral or bodily fluids |
JP2007528982A (en) | 2003-12-19 | 2007-10-18 | メデアー アーベー | Liquid or gas sensor and method |
US20050171816A1 (en) * | 2004-02-04 | 2005-08-04 | Meinert Edward F. | Substance abuse management system and method |
US6967581B2 (en) * | 2004-04-07 | 2005-11-22 | Harry Karsten | Breath alcohol detection system with identity verification |
US7610919B2 (en) | 2004-05-28 | 2009-11-03 | Aetherworks Ii, Inc. | Intraoral aversion devices and methods |
US7716383B2 (en) | 2004-09-27 | 2010-05-11 | Symwave, Inc. | Flash-interfaced fingerprint sensor |
US7421882B2 (en) | 2004-12-17 | 2008-09-09 | University Of Iowa Research Foundation | Breath-based sensors for non-invasive molecular detection |
US20060167723A1 (en) * | 2005-01-21 | 2006-07-27 | Berg L M | Method of treating dependencies |
EP2305104B1 (en) | 2005-03-01 | 2018-10-17 | Masimo Laboratories, Inc. | Multiple wavelength sensor drivers |
CN101193588A (en) | 2005-03-21 | 2008-06-04 | 海尔思-斯玛特有限公司 | System for continuous blood pressure monitoring |
US20060229914A1 (en) * | 2005-04-12 | 2006-10-12 | Armstrong Ronald K Ii | Method of providing support for, and monitoring of, persons recovering from addictive behaviors, mental health issues, and chronic health concerns |
US7481292B2 (en) * | 2005-04-25 | 2009-01-27 | Monitech, Inc. | Vehicle ignition interlock systems with retesting frequency control |
WO2006117771A1 (en) | 2005-05-01 | 2006-11-09 | Flowmedic Limited | A computerized portable device for the enhancement of circulation |
US8079079B2 (en) | 2005-06-29 | 2011-12-13 | Microsoft Corporation | Multimodal authentication |
US20070209669A1 (en) | 2006-03-09 | 2007-09-13 | Derchak P Alexander | Monitoring and quantification of smoking behaviors |
US20070282930A1 (en) * | 2006-04-13 | 2007-12-06 | Doss Stephen S | System and methodology for management and modification of human behavior within a goal-oriented program |
WO2007134040A1 (en) * | 2006-05-08 | 2007-11-22 | Resource Management International, Llc | Personal breathalyzer having digital circuitry |
US20070277836A1 (en) | 2006-06-05 | 2007-12-06 | Longley William H | Apparatuses, Systems and Methods for Determining Compliant Use of an Oral Appliance |
US20070282226A1 (en) * | 2006-06-05 | 2007-12-06 | Longley William H | Apparatuses, Systems and Methods for Monitoring Conditions in an Oral Cavity |
CA2688744A1 (en) * | 2006-12-13 | 2008-06-26 | Bbw Holdings Llc | A method and apparatus for a self-service kiosk system for collecting and reporting blood alcohol level |
US8652040B2 (en) | 2006-12-19 | 2014-02-18 | Valencell, Inc. | Telemetric apparatus for health and environmental monitoring |
US7953613B2 (en) * | 2007-01-03 | 2011-05-31 | Gizewski Theodore M | Health maintenance system |
JP4347345B2 (en) * | 2007-01-15 | 2009-10-21 | 日本電気株式会社 | Alcohol testing apparatus and alcohol testing method |
US20080221418A1 (en) | 2007-03-09 | 2008-09-11 | Masimo Corporation | Noninvasive multi-parameter patient monitor |
WO2009036150A2 (en) | 2007-09-11 | 2009-03-19 | Aid Networks, Llc | Wearable wireless electronic patient data communications and physiological monitoring device |
CN101464467A (en) * | 2007-12-21 | 2009-06-24 | 深圳富泰宏精密工业有限公司 | Multifunctional portable electronic device |
US8160279B2 (en) | 2008-05-02 | 2012-04-17 | Sonitus Medical, Inc. | Methods and apparatus for transmitting vibrations |
US8359901B2 (en) * | 2008-05-28 | 2013-01-29 | LifeSafer Interlock | Chemical impairment detection system and method of use to reduce circumvention |
US8560010B2 (en) * | 2008-06-25 | 2013-10-15 | Wade Koehn | Cell phone with breath analyzer |
CN102089763A (en) | 2008-07-10 | 2011-06-08 | 伊西康内外科公司 | Medical system which controls delivery of a drug and which includes a backpack pouch |
US20100009324A1 (en) * | 2008-07-14 | 2010-01-14 | E. Keith Owens | Method and device for post clinical treatment of dependency relapses |
CA2731040C (en) * | 2008-07-17 | 2013-10-15 | Consumer Safety Technology, Inc. | Ignition interlock breathalyzer |
US20100298683A1 (en) | 2008-09-17 | 2010-11-25 | Deltin Corporation, A California Corporation | Physiological monitoring devices and methods |
CN102341031A (en) * | 2009-01-06 | 2012-02-01 | 普罗秋斯生物医学公司 | Ingestion-related biofeedback and personalized medical therapy method and system |
US8529462B2 (en) * | 2009-02-06 | 2013-09-10 | Justice Ez Trac, Llc | Apparatus and method for passive testing of alcohol and drug abuse |
US8224667B1 (en) * | 2009-02-06 | 2012-07-17 | Sprint Communications Company L.P. | Therapy adherence methods and architecture |
US8280436B2 (en) * | 2009-03-13 | 2012-10-02 | Harris Jr Patrick G | Wireless telephony device with breath analysis sensor and methods for use therewith |
US8381573B2 (en) * | 2009-10-02 | 2013-02-26 | Brad Keays | Sobriety monitoring system |
US9420971B2 (en) | 2009-10-24 | 2016-08-23 | Carrot Sense, Inc. | Extracorporeal devices and methods for facilitating cessation of undesired behaviors |
CA2782512A1 (en) | 2009-12-02 | 2011-06-09 | Neetour Medical Ltd. | Hemodynamics-based monitoring and evaluation of a respiratory condition |
US8830068B2 (en) | 2010-09-15 | 2014-09-09 | Colorado State University Research Foundation | Multi-sensor environmental and physiological monitor system and methods of use |
US20120115115A1 (en) * | 2010-10-18 | 2012-05-10 | Darion Rapoza | Contingency Management Behavioral Change Therapy with Virtual Assets and Social Reinforcement as Incentive-Rewards |
-
2010
- 2010-10-22 US US12/910,371 patent/US9675275B2/en active Active
-
2017
- 2017-06-09 US US15/619,109 patent/US20170319105A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110270053A1 (en) * | 2004-05-28 | 2011-11-03 | David Scott Utley | Intra-Oral Detector and System for Modification of Undesired Behaviors and Methods Thereof |
US20070072156A1 (en) * | 2005-08-05 | 2007-03-29 | Abk Ventures | Lifestyle coach behavior modification system |
WO2008006150A1 (en) * | 2006-07-11 | 2008-01-17 | Citech Research Ip Pty Ltd | Bio-activity data capture and transmission |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11653878B2 (en) | 2009-10-24 | 2023-05-23 | Pivot Health Technologies Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US10306922B2 (en) | 2015-04-07 | 2019-06-04 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US10674761B2 (en) | 2015-04-07 | 2020-06-09 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US11412784B2 (en) | 2015-04-07 | 2022-08-16 | Pivot Health Technologies Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US10335032B2 (en) | 2017-10-10 | 2019-07-02 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US10674913B2 (en) | 2017-10-10 | 2020-06-09 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US11278203B2 (en) | 2017-10-10 | 2022-03-22 | Carrot, Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US11992288B2 (en) | 2017-10-10 | 2024-05-28 | Pivot Health Technologies Inc. | Systems and methods for quantification of, and prediction of smoking behavior |
US11257583B2 (en) | 2019-12-30 | 2022-02-22 | Carrot, Inc. | Systems and methods for assisting individuals in a behavioral-change program |
US11568980B2 (en) | 2019-12-30 | 2023-01-31 | Pivot Health Technologies Inc. | Systems and methods for assisting individuals in a behavioral-change program |
Also Published As
Publication number | Publication date |
---|---|
US9675275B2 (en) | 2017-06-13 |
US20110263947A1 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170319105A1 (en) | Systems and methods for quantification of, and prediction of smoking behavior | |
US11653878B2 (en) | Systems and methods for quantification of, and prediction of smoking behavior | |
US11412784B2 (en) | Systems and methods for quantification of, and prediction of smoking behavior | |
US11992288B2 (en) | Systems and methods for quantification of, and prediction of smoking behavior | |
US11257583B2 (en) | Systems and methods for assisting individuals in a behavioral-change program | |
US20240081647A1 (en) | Systems and methods for assisting in smoking cessation | |
BR112017021701B1 (en) | METHODS FOR QUANTIFYING INDIVIDUAL SMOKING BEHAVIOR AND DEVICE FOR OBTAINING DATA TO QUANTIFY INDIVIDUAL SMOKING BEHAVIOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARROT SENSE, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UTLEY, DAVID S.;REEL/FRAME:043054/0302 Effective date: 20150331 Owner name: UTLEY, DAVID S., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UTLEY, JACK D.;UTLEY, KATHRYN M.;UTLEY, ALEK D.;AND OTHERS;SIGNING DATES FROM 20101028 TO 20101030;REEL/FRAME:043054/0258 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CARROT, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:CARROT SENSE, INC.;REEL/FRAME:044126/0678 Effective date: 20170808 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: PIVOT HEALTH TECHNOLOGIES INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:CARROT INC.;REEL/FRAME:059858/0305 Effective date: 20220310 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |